<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>non-small cell lung cancer &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/non-small-cell-lung-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 19 Jan 2026 19:44:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>non-small cell lung cancer &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Double-Dose Firmonertinib Boosts EGFR L858R Lung Cancer Treatment</title>
		<link>https://bioengineer.org/double-dose-firmonertinib-boosts-egfr-l858r-lung-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 19:43:46 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Based on the content describing a phase II trial on double-dose firmonertinib for EGFR L858R-mutant NSCLC]]></category>
		<category><![CDATA[Double-dose therapy** **Reasoning:** 1. **Firmonertinib:** The primary drug being studied. 2. **EGFR L858R mutation:** The specific genetic target of the treatment. 3. **]]></category>
		<category><![CDATA[EGFR L858R mutation]]></category>
		<category><![CDATA[Faz II Klinik Çalışma** **Açıklama:** 1. **EGFR L858R:** Makalenin tam odak noktası ol]]></category>
		<category><![CDATA[Firmonertinib]]></category>
		<category><![CDATA[Hedefe Yönelik Tedavi]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Firmonertinib]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket (virgülle ayrılmış): **EGFR L858R]]></category>
		<category><![CDATA[Non-Küçük Hücreli Akciğer Kanseri]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[phase II trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/double-dose-firmonertinib-boosts-egfr-l858r-lung-cancer-treatment/</guid>

					<description><![CDATA[A groundbreaking advancement in the fight against non-small-cell lung cancer (NSCLC) has emerged from a recent multicenter phase II study exploring the efficacy of double-dose firmonertinib as a first-line treatment for patients harboring the EGFR L858R mutation. This study, led by Shen, Wang, Zhang, and colleagues, impeccably combines innovative pharmacological intervention with rigorous clinical methodology, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318526</post-id>	</item>
		<item>
		<title>Liquid Biopsy AI Enhances Lung Cancer Progression Predictions</title>
		<link>https://bioengineer.org/liquid-biopsy-ai-enhances-lung-cancer-progression-predictions/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 06 Jan 2026 07:03:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Cancer progression prediction]]></category>
		<category><![CDATA[İşte bu içerik için uygun 5 etiket: **AI in oncology]]></category>
		<category><![CDATA[kanser araştırmalarında yapay zekanın (özellikle PRIME modelinin) kullanımıdır. 2. **Liquid biopsy:**]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[Personalized medicine** **Açıklama:** 1. **AI in oncology:** Makalenin ana konusu]]></category>
		<guid isPermaLink="false">https://bioengineer.org/liquid-biopsy-ai-enhances-lung-cancer-progression-predictions/</guid>

					<description><![CDATA[In a remarkable breakthrough in cancer research, an innovative artificial intelligence model named PRIME (Predictive Risk Indicator for Metastasis and Extension) has been developed to enhance the prediction of progression risks in patients suffering from non-small cell lung cancer (NSCLC). This pioneering research, conducted by a team led by Dr. Y. Wang, has shown promising [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314046</post-id>	</item>
		<item>
		<title>Radiotherapy Boosts Immunotherapy Survival in Bone-Metastatic NSCLC</title>
		<link>https://bioengineer.org/radiotherapy-boosts-immunotherapy-survival-in-bone-metastatic-nsclc/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 24 Dec 2025 00:17:29 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[İşte 5 uygun etiket (virgülle ayrılmış): **Bone metastases]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[özellikle NSCLC'deki kemik metastazlarının tedavisindeki gelişmelerdir. 2.]]></category>
		<category><![CDATA[Radiotherapy]]></category>
		<category><![CDATA[Survival rates** **Seçimlerimin Gerekçesi:** 1. **Bone metastases:** Makalenin odak noktası]]></category>
		<guid isPermaLink="false">https://bioengineer.org/radiotherapy-boosts-immunotherapy-survival-in-bone-metastatic-nsclc/</guid>

					<description><![CDATA[In a groundbreaking commentary published in the ‘Journal of Cancer Research and Clinical Oncology’, Dr. P. Peker sheds light on the significant advancements in treatment strategies for bone-metastatic non-small cell lung cancer (NSCLC). This malignancy, notorious for its challenging prognosis, often presents treatment hurdles that medical practitioners and researchers alike strive to overcome. The incorporation [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">310764</post-id>	</item>
		<item>
		<title>Evodiamine Targets Genes in Cisplatin-Resistant Lung Cancer</title>
		<link>https://bioengineer.org/evodiamine-targets-genes-in-cisplatin-resistant-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Dec 2025 08:27:20 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cisplatin resistance]]></category>
		<category><![CDATA[differential gene expression]]></category>
		<category><![CDATA[Drug resistance reversal]]></category>
		<category><![CDATA[Evodiamine]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/evodiamine-targets-genes-in-cisplatin-resistant-lung-cancer/</guid>

					<description><![CDATA[In a groundbreaking study that delves into the molecular mechanisms of chemotherapy resistance, researchers have unveiled promising insights into the use of Evodiamine as a potential therapeutic agent against cisplatin-resistant non-small cell lung cancer (NSCLC). Cisplatin, a platinum-based chemotherapy drug, is a cornerstone in the treatment of NSCLC, yet its efficacy is often thwarted by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">305630</post-id>	</item>
		<item>
		<title>New lncRNA Drives Cisplatin Resistance in Lung Cancer</title>
		<link>https://bioengineer.org/new-lncrna-drives-cisplatin-resistance-in-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 27 Nov 2025 16:00:45 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Chemoresistance mechanisms]]></category>
		<category><![CDATA[cisplatin resistance]]></category>
		<category><![CDATA[glycolysis]]></category>
		<category><![CDATA[lncRNA]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-lncrna-drives-cisplatin-resistance-in-lung-cancer/</guid>

					<description><![CDATA[In an unprecedented breakthrough, researchers have uncovered a revolutionary molecular mechanism behind chemoresistance in non-small cell lung cancer (NSCLC), focusing on a novel long non-coding RNA (lncRNA) named RP11-544M22.13. This discovery could signify a paradigm shift in our understanding of cancer metabolism and therapeutic resistance, potentially steering new strategies to combat one of the deadliest [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">302397</post-id>	</item>
		<item>
		<title>PinX1 Silencing Boosts Radiotherapy Efficacy in Lung Cancer</title>
		<link>https://bioengineer.org/pinx1-silencing-boosts-radiotherapy-efficacy-in-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 25 Sep 2025 18:25:55 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[antitumor immunity]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[PinX1 silencing]]></category>
		<category><![CDATA[radiosensitivity enhancement]]></category>
		<category><![CDATA[radiotherapy efficacy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/pinx1-silencing-boosts-radiotherapy-efficacy-in-lung-cancer/</guid>

					<description><![CDATA[Recent research highlights the potential of targeting PinX1 in the treatment of non-small cell lung cancer (NSCLC), particularly in enhancing radiosensitivity and antitumor immunity. This study, conducted by Qiu et al., addresses a critical understanding of how silencing the PinX1 gene can amplify the effects of radiotherapy. The implications of these findings are vast and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">272342</post-id>	</item>
		<item>
		<title>Case Study: Significant Tumor Response in Non-Small Cell Lung Cancer with SMARCA4 Deficiency and Rare EGFR Mutations Following Afatinib Treatment</title>
		<link>https://bioengineer.org/case-study-significant-tumor-response-in-non-small-cell-lung-cancer-with-smarca4-deficiency-and-rare-egfr-mutations-following-afatinib-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 01 Apr 2025 15:29:14 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[afatinib treatment]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[rare EGFR mutations]]></category>
		<category><![CDATA[SMARCA4 deficiency]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/case-study-significant-tumor-response-in-non-small-cell-lung-cancer-with-smarca4-deficiency-and-rare-egfr-mutations-following-afatinib-treatment/</guid>

					<description><![CDATA[Lung cancer remains a leading cause of cancer-related mortality worldwide, with various subtypes exhibiting unique molecular characteristics and treatment responses. Among these subtypes, non-small cell lung cancer (NSCLC) with SMARCA4 deficiency has garnered significant attention due to its aggressive nature and poor prognosis. Studies reveal that tumors with this deficiency are often characterized by a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">239698</post-id>	</item>
		<item>
		<title>Fighting Osimertinib Resistance in Lung Cancer Treatment</title>
		<link>https://bioengineer.org/fighting-osimertinib-resistance-in-lung-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Nov 2023 18:43:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[brigatinib]]></category>
		<category><![CDATA[C797S mutation]]></category>
		<category><![CDATA[C797S/T790M mutations]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[clinical studies]]></category>
		<category><![CDATA[EGFR amplification]]></category>
		<category><![CDATA[EGFR exon 18 mutations]]></category>
		<category><![CDATA[EGFR exon 20 mutations]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[EGFR-TKI]]></category>
		<category><![CDATA[fourth generation TKI]]></category>
		<category><![CDATA[health research]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[innovations in cancer treatment]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[molecular treatment methods]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[ORCHARD trial]]></category>
		<category><![CDATA[osimertinib resistance]]></category>
		<category><![CDATA[osimertinib treatment]]></category>
		<category><![CDATA[PD-1]]></category>
		<category><![CDATA[PD-L1]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=217045</guid>

					<description><![CDATA[Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) constitutes approximately 85%, posing significant challenges for patients and healthcare professionals, especially due to its late-stage diagnosis and complex treatment processes. However, the last decade has witnessed transformative advancements in molecular biology and drug development, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">217045</post-id>	</item>
	</channel>
</rss>
